Recombinant Human FLT4
Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Recombinant Human FLT4
category
Proteins and Peptides
provider
FineTest
reference
P2180
tested applications
Western Blot, ELISA
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | 1188-1348 |
| Host | E.Coli |
| Origin | Human |
| Observed MW | 38.5 kDa |
| Expression | Recombinant |
| Purity | Greater than 95% by SDS-PAGE gel analyses |
| Purification | IF2DI tag |
| Size 1 | 50μg |
| Size 2 | 200μg |
| Size 3 | 1mg |
| Form | Lyophilized from a 0.2um filtered solution in PBS with 5% trehalose, pH7.4 |
| Tested Applications | Western Blot, ELISA |
| Buffer | Reconstitute with Sterile distilled water |
| Availability | 7 days |
| Storage | -20°C for 12 months as lyophilized;2-8°C for 1 month under sterile conditions after reconstitution |
| UniProt ID | P35916 |
| Alias | PCL,CHTD7,FLT-4,FLT41,LMPH1A,LMPHM1,VEGFR3,VEGFR-3,Tyrosine-protein kinase receptor FLT4,Fms-like tyrosine kinase 4,Vascular endothelial growth factor receptor 3 |
| Background | Proteins FLT4 |
| Status | RUO |
| Note | This product is for research use only. |
Fms related receptor tyrosine kinase 4 (FLT4) FLT4, also known as vascular endothelial growth factor receptor 3 (VEGFR3), is a receptor tyrosine kinase critical for the regulation of lymphangiogenesis, the formation of lymphatic vessels. Structurally, FLT4 comprises an extracellular domain with seven immunoglobulin-like loops, a single transmembrane domain, and an intracellular tyrosine kinase domain. FLT4 binds VEGF-C and VEGF-D ligands, leading to receptor dimerization and activation of downstream signaling pathways, including the MAPK and PI3K-AKT cascades. These pathways are essential for lymphatic endothelial cell proliferation, migration, and survival. FLT4 is predominantly expressed in lymphatic endothelial cells, where it plays a pivotal role in maintaining lymphatic vessel integrity and fluid homeostasis. Dysregulation of FLT4 has been linked to lymphedema, a condition characterized by lymphatic fluid accumulation, and its overexpression has been implicated in cancer progression, where it promotes tumor lymphangiogenesis and metastasis. FLT4 is a promising therapeutic target for modulating lymphatic function in both pathological and developmental contexts.
Related Products
Human FLT4(Vascular endothelial growth factor receptor 3) ELISA Kit
Ver Producto
Mouse VEGFR3/FLT4(Vascular Endothelial Cell Growth Factor Receptor 3) ELISA Kit
Ver Producto